AbbVie News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

09.03.22	AbbVie Resolves All U.S. HUMIRA Litigation With Alvotech (RTTNews)
08.03.22	AbbVie Resolves HUMIRA® (adalimumab) U.S. Litigation with Alvotech (PR Newswire)
02.03.22	Harpoon Therapeutics: HPN217 Receives FDA Fast Track Designation (RTTNews)
01.03.22	AbbVie-Aktie im Minus: AbbVie kauft Syndesi Therapeutics zu (Dow Jones) Der US-Pharmakonzern AbbVie verstärkt sein Portfolio im Bereich der Neurowissenschaften und übernimmt die belgische Syndesi Therapeutics.» mehr
01.03.22	AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio (PR Newswire)
28.02.22	AbbVie Provides Update Regarding SKYRIZI® (risankizumab-rzaa) for the Treatment of Moderate to Severe Crohn's Disease in the U.S. (PR Newswire)
28.02.22	AbbVie Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD) (PR Newswire)
24.02.22	Allergan, an AbbVie Company, to Present Data from its Leading Portfolio of Eye Care Treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting (PR Newswire)
24.02.22	ABBV: Phase 3 Study Confirms Upadacitinib Improved Clinical & Endoscopic Outcomes In Crohn's Disease (RTTNews)
24.02.22	Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ®) Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease (PR Newswire)
22.02.22	AbbVie Submits Supplemental New Drug Application to U.S. FDA for cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder (PR Newswire)
17.02.22	AbbVie Declares Quarterly Dividend (PR Newswire)
10.02.22	Healis Therapeutics acquires ownership of key botulinum toxin patent (PR Newswire)
08.02.22	Allergan Aesthetics: FDA Approves JUVÉDERM VOLBELLA XC For Improvement Of Infraorbital Hollows (RTTNews)
08.02.22	FDA Approves JUVÉDERM® VOLBELLA® XC For Undereye Hollows (PR Newswire)
02.02.22	MÄRKTE USA/Überzeugende Quartalszahlen treiben Wall Street weiter an (Dow Jones)
02.02.22	MÄRKTE USA/Wall Street mit Konsolidierung - Alphabet nach Zahlen gesucht (Dow Jones)
02.02.22	MÄRKTE USA/Wall-Street-Rally scheint mit schwachen Daten auszulaufen (Dow Jones)
02.02.22	MÄRKTE USA/Wall-Street-Rally dürfte dank Technologiesektor andauern (Dow Jones)
02.02.22	AbbVie Guides FY22 Adj. EPS Above Estimates - Quick Facts (RTTNews)
02.02.22	AbbVie Q4 Profit Increases, beats estimates (RTTNews)
02.02.22	AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results (PR Newswire)
01.02.22	AbbVie Showcases Its Leadership in Research in Inflammatory Bowel Diseases with New Analyses to be Presented at the 17th Congress of European Crohn's and Colitis Organization (ECCO) (PR Newswire)
01.02.22	Ausblick: AbbVie gewährt Anlegern Blick in die Bücher (finanzen.net)
24.01.22	Allergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic (onabotulinumtoxinA) (PR Newswire)
21.01.22	U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis (PR Newswire)
18.01.22	Erste Schätzungen: AbbVie informiert über die jüngsten Quartalsergebnisse (finanzen.net)
14.01.22	U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis (PR Newswire)
11.01.22	AbbVie Confirms Outlook Of Over $15 Bln In Combined Risk-Adj. Sales For Rinvoq, Skyrizi In 2025 (RTTNews)
11.01.22	AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025 (PR Newswire)
11.01.22	ACELYRIN Appoints Melanie Gloria as Chief Operating Officer (PR Newswire)
07.01.22	AbbVie Submits Applications For Upadacitinib In Non-Radiographic Axial Spondyloarthritis To FDA (RTTNews)
07.01.22	AbbVie Submits Applications for Upadacitinib (RINVOQ®) in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) (PR Newswire)
04.01.22	AbbVie: Teliso-V Gets Breakthrough Therapy Designation (RTTNews)
04.01.22	AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer (PR Newswire)
23.12.21	Top 10 Blockbuster Drugs In 2021 (RTTNews)
16.12.21	Allergan Aesthetics Completes Acquisition of Soliton (PR Newswire)
15.12.21	FDA Approves AbbVie's RINVOQ To Treat Active Psoriatic Arthritis (RTTNews)
15.12.21	RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis (PR Newswire)
14.12.21	Genentech's Polivy Combination Reduces Risk Of Disease Worsening Or Death By 27% In DLBCL (RTTNews)
13.12.21	AstraZeneca Elated On Calquence Data, IMGN's IMGN632 Appears To Be Promising In AML, XRTX On Watch (RTTNews)
09.12.21	Allergan Announces Availability Of FDA-Approved Eye Drop VUITY - Quick Facts (RTTNews)
09.12.21	VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision (Presbyopia), is Now Available (PR Newswire)
06.12.21	AbbVie's Upadacitinib Achieves Primary & Secondary Endpoints In Phase 3 Study On Crohn's Disease (RTTNews)
06.12.21	Upadacitinib (RINVOQ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease (PR Newswire)
03.12.21	AbbVie Provides Update on RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis in the U.S. (PR Newswire)
30.11.21	AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA) (PR Newswire)
19.11.21	Allergan Aesthetics To Present Data From Its Leading Aesthetic Portfolio At The 2021 American Society For Dermatologic Surgery Virtual Meeting (PR Newswire)
18.11.21	New Literature Review Highlights Economic Benefits Associated with Achieving Rheumatoid Arthritis Remission (PR Newswire)
18.11.21	AbbVie Brings VENCLEXTA Plus Obinutuzumab To Chronic Lymphocytic Leukemia Patients In Quebec (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen
02.07.24		Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge
02.07.24		Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten
06.05.24		S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude
26.04.24		Gewinne in New York: S&P 500 am Nachmittag fester

11.11.24

Börse New York in Grün: S&P 500 zum Handelsende freundlich

11.11.24

Optimismus in New York: S&P 500 am Nachmittag mit Kursplus

11.11.24

NYSE-Handel: S&P 500 mittags freundlich

11.11.24

Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen

02.07.24

Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge

02.07.24

Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten